Fluticasone propionate cream yeast

Binds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cells and eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability and subsequent edema, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptor complexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for nuclear factor kappaB1], IL-10, and IL-12. The antiinflammatory actions of corticosteroids are also thought to involve inhibition of cytosolic phospholipase A2 (through activation of lipocortin-1 (annexin)) which controls the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

Initial dose should be based upon previous therapy and asthma severity; consideration should be given to current control of asthma symptoms and risk of future exacerbations:

4 to 11 years:

Fluticasone propionate INHALATION POWDER (Flovent Diskus[R]):
Patients new to ICS: Initial dose: 50 mcg via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum dose: 100 mcg twice a day
Fluticasone propionate INHALATION AEROSOL (Flovent HFA[R]):
88 mcg via oral inhalation twice a day
Maximum dose: 88 mcg twice a day

12 years or older:

Fluticasone propionate INHALATION AEROSOL (Flovent HFA[R]):
Patients new to ICS: Initial dose: 88 mcg via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum Dose: 880 mcg twice a day

Fluticasone propionate INHALATION POWDER (Flovent Diskus[R]):
Patients new to ICS: Initial dose: 100 mcg via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum dose: 1000 mcg twice a day

Fluticasone propionate INHALATION POWDER (Armonair Respiclick[R]): One oral inhalation twice a day
-Initial dose for patients new to ICS: 55 mcg (low dose) via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose of 113 mcg (medium dose) or 232 mcg (high dose) via oral inhalation twice a day
Maximum Dose: 232 mcg twice a day

Fluticasone furoate INHALATION POWDER Arnuity Ellipta[R]):
Patients new to ICS: Initial dose: 100 mcg via oral inhalation once a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum dose: 200 mcg once a day

Comments:
-Higher initial doses may be considered in patients with poor asthma control or those who have previously required higher doses of other ICS.
-Inhaled short-acting beta(2)-agonists should be used for immediate relief if symptoms arise between doses.
-Maximum benefit of ICS may not be achieved for up to 2 weeks or longer; if adequate control is not achieved in 2 weeks, may increase dose without exceeding maximum dose.
-After asthma stability has been achieved, titrate to the lowest effective dose to reduce the possibility of side effects.
-Not indicated for the relief of acute bronchospasm.

Use: For the maintenance treatment of asthma as prophylactic therapy.

Fluticasone propionate cream yeast

fluticasone propionate cream yeast

Media:

fluticasone propionate cream yeastfluticasone propionate cream yeastfluticasone propionate cream yeastfluticasone propionate cream yeastfluticasone propionate cream yeast